USD
+$0.00
(+0.00%
)At Close (As of Sep 8, 2025)
$49.37M
Market Cap
0.562
P/E Ratio
6
EPS
$14.20
52 Week High
$2.64
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $5.9M |
Total Revenue | $17M |
Cost Of Revenue | $11M |
Costof Goods And Services Sold | $11M |
Operating Income | -$37M |
Selling General And Administrative | $31M |
Research And Development | $13M |
Operating Expenses | $43M |
Investment Income Net | - |
Net Interest Income | -$607K |
Interest Income | - |
Interest Expense | $607K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $268K |
Income Before Tax | -$37M |
Income Tax Expense | $725K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$38M |
Comprehensive Income Net Of Tax | - |
Ebit | -$36M |
Ebitda | -$36M |
Net Income | -$38M |
Field | Value (USD) |
---|---|
Total Assets | $60M |
Total Current Assets | $35M |
Cash And Cash Equivalents At Carrying Value | $25M |
Cash And Short Term Investments | $25M |
Inventory | $4.1M |
Current Net Receivables | $4M |
Total Non Current Assets | $25M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $6K |
Intangible Assets Excluding Goodwill | $6K |
Goodwill | $6.9M |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $2.2M |
Other Non Current Assets | - |
Total Liabilities | $28M |
Total Current Liabilities | $12M |
Current Accounts Payable | $3M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $2.1M |
Total Non Current Liabilities | $16M |
Capital Lease Obligations | $4M |
Long Term Debt | $8.9M |
Current Long Term Debt | $1M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $14M |
Other Current Liabilities | $6.3M |
Other Non Current Liabilities | $4.5M |
Total Shareholder Equity | $32M |
Treasury Stock | - |
Retained Earnings | -$295M |
Common Stock | $1.5M |
Common Stock Shares Outstanding | $13M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$22M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $268K |
Capital Expenditures | $158K |
Change In Receivables | - |
Change In Inventory | $986K |
Profit Loss | - |
Cashflow From Investment | $146K |
Cashflow From Financing | $37M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$38M |
Field | Value (USD) |
---|---|
Gross Profit | $5.9M |
Total Revenue | $17M |
Cost Of Revenue | $11M |
Costof Goods And Services Sold | $11M |
Operating Income | -$37M |
Selling General And Administrative | $31M |
Research And Development | $13M |
Operating Expenses | $43M |
Investment Income Net | - |
Net Interest Income | -$607K |
Interest Income | - |
Interest Expense | $607K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $268K |
Income Before Tax | -$37M |
Income Tax Expense | $725K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$38M |
Comprehensive Income Net Of Tax | - |
Ebit | -$36M |
Ebitda | -$36M |
Net Income | -$38M |
Field | Value |
---|---|
Ex Dividend Date | 2014-04-28 |
Declaration Date | None |
Record Date | None |
Payment Date | None |
Amount | 0.07 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Veru Inc., an oncology biopharmaceutical company, focuses on the development of drugs for the treatment of cancers. The company is headquartered in Miami, Florida.